CALCR and cancer: We have recently described the increased expression of CTR in the brain tumour glioblastoma.25 In an effort to understand the role of CTR in this type of cancer, we developed a novel CTR ligand consisting of a fluorescently coupled anti-CTR monoclonal antibody directed against an extracellular, N-terminal epitope (mAb2C4:AF568).